David Clay, MD
Internal Medicine · Fayetteville, ARNPI 1093741910
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 447 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by GSK at 31.7% of the total. Reporting peaked in 2022 at $1,187 and has fallen 53.8% since, to $548 in 2025. Among internal medicine clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 447 payments — averaging $13.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AbbVie$1K
- Pfizer$807
- AstraZeneca$676
- Novo Nordisk$265
- Teva Pharmaceuticals USA, Inc.$135
- plus $913 from 23 others
What the payments were for
- Food & beverage$6,070100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 154 | $1,927 |
| AbbVie(2 entities) | 91 | $1,353 |
| Pfizer | 71 | $807 |
| AstraZeneca | 36 | $676 |
| Novo Nordisk | 24 | $265 |
| Teva Pharmaceuticals USA, Inc. | 9 | $135 |
| CSL Behring | 5 | $94 |
| Sanofi | 4 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $78 |
| Dexcom, Inc. | 6 | $77 |
| Amgen(2 entities) | 5 | $75 |
| Grifols USA, LLC | 4 | $72 |
| Regeneron Healthcare Solutions, Inc. | 3 | $50 |
| Novartis | 3 | $43 |
| Merck | 3 | $40 |
| Astellas Pharma US Inc | 3 | $35 |
| Johnson & Johnson(2 entities) | 2 | $30 |
| Boehringer Ingelheim | 2 | $30 |
| Lilly USA, LLC | 2 | $29 |
| Philips North America LLC | 2 | $28 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| Genentech USA, Inc. | 2 | $23 |
| Actelion Pharmaceuticals US, Inc. | 1 | $22 |
| Advanced Respiratory, Inc | 1 | $19 |
| United Therapeutics Corporation | 1 | $16 |
| Axonics, Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $12 |
| Mallinckrodt Enterprises LLC | 1 | $12 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,076 in reported general payments places this provider in the 90th percentile of 614 internal medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProcysbiCysteamine Bitartrate | 11 | $473,072 |
| EliquisApixaban | 213 | $170,329 |
| XareltoRivaroxaban | 136 | $112,827 |
| OzempicSemaglutide | 91 | $90,460 |
| JardianceEmpagliflozin | 80 | $77,875 |
| MounjaroTirzepatide | 59 | $71,977 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 73 | $62,941 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 47 | $20,228 |
| JanuviaSitagliptin Phosphate | 18 | $18,694 |
| MyrbetriqMirabegron | 24 | $18,388 |
| LinzessLinaclotide | 23 | $12,294 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $9,286 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 69 | $8,631 |
| PremarinEstrogens, Conjugated | 17 | $8,575 |
| SynthroidLevothyroxine Sodium | 86 | $6,911 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenProcysbi | $75 | $473,07211 claims |
| PfizerEliquis, Premarin, Paxlovid | $807 | $181,762260 claims |
| Johnson & JohnsonXarelto | $30 | $112,827136 claims |
| Novo NordiskOzempic | $265 | $90,46091 claims |
| Boehringer IngelheimJardiance, Pradaxa | $30 | $79,88592 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,927 | $72,22796 claims |
| Lilly USA, LLCMounjaro | $29 | $71,97759 claims |
| AbbVieLinzess, Synthroid | $1,353 | $19,206109 claims |
| MerckJanuvia | $40 | $18,69418 claims |
| Astellas Pharma US IncMyrbetriq | $35 | $18,38824 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $23 | $6,376199 claims |
| AstraZenecaSymbicort | $676 | $3,11214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 614 internal medicine providers in Arkansas.
Other internal medicine in Fayetteville
- Scott BirchFayetteville$7K
- David PyleJonesboro$93K
- Aaron StrobelLittle Rock$32K
- Stuart BensonRogers$24K
- Purnima SarkarEarle$21K
- John NorwoodJonesboro$21K
- Ahmed AliConway$18K
- Jeremy DavisLittle Rock$17K
- Tyree SealsFort Smith$14K
- Atif KhanBatesville$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.